BC200 (BCYRN1) – The shortest, long, non-coding RNA associated with cancer

J. Samson, S. Cronin, K. Dean*

School of Biochemistry and Cell Biology, Western Gateway Building, University College Cork, Cork, Ireland

ARTICLE INFO

Article history:
Received 8 December 2017
Received in revised form
14 May 2018
Accepted 17 May 2018
Available online 22 May 2018

Keywords:
Long non-coding RNA
lncRNA
Cancer
BC200
BCYRN1
Translational regulation
RNA-protein interactions

ABSTRACT

With the discovery that the level of RNA synthesis in human cells far exceeds what is required to express protein-coding genes, there has been a concerted scientific effort to identify, catalogue and uncover the biological functions of the non-coding transcriptome. Long, non-coding RNAs (lncRNAs) are a diverse group of RNAs with equally wide-ranging biological roles in the cell. An increasing number of studies have reported alterations in the expression of lncRNAs in various cancers, although unravelling how they contribute specifically to the disease is a bigger challenge. Originally described as a brain-specific, non-coding RNA, BC200 (BCYRN1) is a 200-nucleotide, predominantly cytoplasmic lncRNA that has been linked to neurodegenerative disease and several types of cancer. Here we summarise what is known about BC200, primarily from studies in neuronal systems, before turning to a review of recent work that aims to understand how this lncRNA contributes to cancer initiation, progression and metastasis, along with its possible clinical utility as a biomarker or therapeutic target.

© 2018 Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Over the past ten years, advances in sequencing technologies have led to the discovery that the human genome is widely transcribed into RNA; however, only 2% of the RNA produced is translated into proteins [1,2]. This means that the cellular contribution of the non-coding transcriptome is expanding. In particular, long, non-coding RNAs (lncRNAs) have emerged as regulators of normal cellular events and various disease states, including cancer [3,4].

As one class of non-coding RNAs, lncRNAs are defined as transcripts greater than 200 nucleotides and containing little or no protein-coding potential. The size criterion distinguishes lncRNAs from smaller, non-coding RNAs, such as microRNAs (miRNAs) and piwi-interacting RNAs (piRNAs) [5,6]. Studies indicate that most lncRNAs are synthesised by RNA polymerase II (Pol II) and are processed similarly to messenger RNAs (mRNAs), with capping, splicing and polyadenylation [7]. However, some lncRNAs, like Pol II transcript metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), have unique processing events that distinguish them from mRNAs [8,9]. In addition to Pol II transcription, some lncRNAs are transcribed by RNA polymerase III (Pol III) [10,11], adding another level of transcripational complexity to this class of non-coding RNAs.

Not surprisingly, much scientific effort has been directed towards the discovery and annotation of lncRNAs in humans [12,13]. This has subsequently led to a proliferation of specialized lncRNA databases, such as NONCODEv5 [14] that integrates data from the genomes of 17 different species and LNCipedia [15] that contains close to 150,000 human annotated lncRNAs.

With tens of thousands of lncRNAs in human cells [14,16], there are significant challenges to understand their cellular roles, particularly as lncRNAs are often expressed at lower levels than mRNAs and exhibit poor sequence conservation across various species [17]. However, lack of sequence conservation does not equate to lack of function [18]. In recent years, significant progress has been made in characterising biological functions of lncRNAs. There are now many examples of lncRNAs affecting cellular processes like development, differentiation and proliferation, in addition to their impact at every level of gene expression from chromatin remodeling to translation [3,4,9,19–22].

This review will focus on BC200, an lncRNA that was first discovered in primate brain in 1987 [23]. Conserved in humans [24], initial studies on human BC200 were focused on its neural-specific, dendritic localisation [25]. A link to cancer was provided a few years later by a key study revealing BC200 RNA expression in...
a number of human tumours by Northern blot analysis and in situ hybridization [26]. In that study, the authors found BC200 expression to be substantially increased in certain tumours, like breast, cervix, oesophagus, lung, ovary, parotid and tongue, while it is undetectable in corresponding normal tissues and in other cancers, such as bladder, colon and liver [26]. More recent investigations propose that BC200 has roles in cell migration, proliferation and survival [27–34] — all suggesting that BC200 contributes to cancer development and progression.

In this review, we outline the general features of BC200 lncRNA, including its transcription, sequence elements and expression patterns. We then refer to BC200’s evolutionary emergence and detail its analogues. To better understand BC200’s functional significance, we present current knowledge of the RNA’s protein interactions within the cell, highlighting several recent publications. Lastly, BC200’s association with human disease, focusing on cancer, is discussed, along with the use of BC200 as a cancer diagnostic or prognostic biomarker.

2. Overview of BC200 lncRNA

2.1. Features of BC200 from transcription to cellular localisation

2.1.1. BC200 biosynthesis

BC200, also known as brain cytoplasmic RNA 1 (BCYRN1), is a non-coding RNA, sense-transcribed from its gene locus situated on human chromosome 2 between the protein-coding genes for calmodulin 2 (CALM2) and epithelial cellular adhesion molecule (EPICAM) [35,36]. BC200 was the first example of a primate, tissue-specific Pol III transcript [37], altering the view that Pol III was only responsible for the synthesis of transfer RNA (tRNA) and 5 S ribosomal RNA (rRNA) [10,11].

Recent work from Kim et al. (2017) offers an in-depth analysis of BC200 biosynthesis [38]. Prior to this study, analysis of the BC200 promoter region included the identification of a putative TATA box and two internal A and B box promoter elements [39], which are common features of Pol III promoters [11,40]. With their study, Kim et al. confirmed the critical role of the TATA box and internal promoter elements for BC200 transcription. In addition, the authors demonstrated that the 100-base pair (bp) region upstream to BC200 transcription start site (TSS) is characterized by two distinct regions: –100 to –36 bp, which is bound by transcription factors independent to the internal promoter elements, and a –35 to –6 bp region in which the binding of transcription factors is dependent on the A and B box elements (Fig. 1A).

The authors further revealed that TATA binding protein (TBP) binds to the –100 bp region in human cervical carcinoma (HeLa) cells and that a deletion of the TATA box leads to an impaired BC200 transcription [38]. Indeed the TATA box and TBP-binding seems to be part of a conserved core promoter that is required for all eukaryotic polymerases [41].

While core promoter elements are essential for basal transcription, further levels of transcriptional regulation can be achieved by specific transcription factors binding to promoter elements and influencing transcriptional output. With regard to BC200 synthesis, two studies have examined the influence of specific transcription factors, c-MYC [27] and estrogen receptor α (ERα) [28], in lung and breast cancer cell lines respectively. Given that the MYC proto-oncogene is deregulated in many cancers [42,43], it remains to be seen if MYC drives BC200 expression in other cancers besides non-small cell lung cancer (NSCLC) [27]. Like other promoters, the specific transcription factors that regulate BC200 transcription at any given time will likely be dependent on cell type and context. Therefore, in addition to experimentally identifying the members of BC200 transcriptional network, it will be important to understand how the network is integrated and regulated within a wider cellular environment. Certainly there is still much to be discovered about the specific details BC200 biosynthesis, particularly in diseased cells.

2.1.2. BC200: structural elements and cellular localisation

Named after the length of its unique single exon of 200 nucleotides [23,25], sequence analysis of BC200 RNA sequence revealed three distinct sequence domains: a 5’ Alu element, a central adenosine-rich region and a 3’, 43-nucleotide, unique region containing a cytosine-rich stretch [25] (Fig. 1B). Unlike many lncRNAs that remain and function in the nucleus, BC200 is classified as a small, cytoplasmic RNA (Ensembl release 90) [44]. Importantly, many of its molecular interactions involve proteins located in the cytoplasm (described in the following section). Initial evidence for its cytoplasmic location was based on its presence in the cytoplasmic, poly(A)- RNA fraction of monkey and human brain samples [23]. More recent experiments have involved cell fractionation followed by quantitative, reverse transcription, polymerase chain reaction (qRT-PCR) to monitor relative expression levels of BC200 in nuclear versus cytoplasmic fractions [28,30]. In these experiments, BC200 is primarily present in the cytoplasm; however, it should be pointed out that there is a small, but detectable amount of BC200 in the nuclear fraction as well [28,30]. In an alternative approach using an antibody directed against BC200 RNA, Shin et al. (2017) observed punctate staining in both the cytoplasm and nucleus of cervical carcinoma cells and localisation of BC200 with proteins in processing bodies (P bodies) [45]. Taken together, BC200 is largely cytoplasmic; yet, with evidence that the RNA modulates alternative splicing of an apoptotic regulator protein, Bcl-x (B cell lymphoma 2 family member) [28], additional nuclear functions for BC200 cannot be ruled out.

2.1.3. BC200: confirmation of non-coding status

One surprising experimental observation in the lncRNA field has been that cytoplasmic lncRNAs are often found associated with translational machinery through ribosome profiling data [46,47], calling into the question their non-coding status. A study by Carlevaro-Fita et al. (2016) raises the possibility that the ribosome may play a role in regulating the degradation of cytoplasmic lncRNAs [48]. Interestingly, an increasing number of reports demonstrate that non-coding transcripts might in fact code for small peptides [46,49]. The identification of these peptide-coding, ‘non-coding’ RNAs remains difficult. As ribosome occupancy alone is not proof of the coding status [50], it still hints at the coding potential of the transcript. Indeed the line between lncRNAs and mRNAs is blurred, and it is not as clear cut as once was assumed [51,52]. In examining the coding potential of BC200 using published ribosome profiling data [53–57] in the GWIPS-viz Genome Browser from RiboGalaxy [58], we confirmed that BC200 does not associate with ribosomes, reflecting its true non-coding status as previously described [37].

2.1.4. BC200: tissue and cell-type expression

Indicative of its name, BC200 is found in the primate brain [23,25]. Among neural cells, BC200 is highly expressed in dendrites, where is it thought to play a role in local translational control [24,25,59–62]. Given its expression in the nervous system, there have been numerous studies examining BC200’s molecular interactions in neurons [63–68], along with reports examining the precise function of BC200 [60,62]. The reader is referred to a recent review by Sosińska et al. [69] that comprehensively addresses what is known about BC200 in the regulation of neuronal gene expression.
Fig. 1. Schematic representation of human BC200 promoter region, secondary structure and sequence similarity to 7SL and BC 1 RNAs.

(A) The BC200 promoter is divided into three domains. The first is transcription factor (TF) binding site I located between position –100 and –36 bp. The second is TF binding site II located between –35 bp and –6 bp, which contains a TATA box. The binding of TFs to this region is dependent on the third domain, containing two internal promoter elements, A box and B box. TATA binding protein (TBP) binds to the BC200 promoter in the region located between –100 bp to 30 bp [38]. Additional transcription factors that influence the BC200 promoter are not shown. (B) Folding parameters of BC200 RNA (accession number NR038088.1) were determined by mFold [156] and used in Jarna, an RNA secondary structure visualization tool [157]. Structural elements are colour-coded as follows: Green – stems (canonical helices); red – multiloops/junctions; yellow – interior loops; blue – hairpin loops; orange – 3’ unpaired region. The Alu-like, A-rich and unique regions of BC200 are indicated. (C) Pairwise alignment of BC200 with 7SL (human; accession number X04248.1) and BC1 (mouse; accession number NR001568.1) using MultiAlin [158]. Nucleotides are coloured blue if they are identical between two of the three RNAs; red indicates identical nucleotides among the three non-coding RNAs.
Outside of neural tissue, BC200 is expressed in testes and ovary [30]; however, for this review, our focus is on BC200’s link to various cancers. While BC200 is present in non-neuronal immortalized cell lines [30], it was a seminal study by Chen et al. that provided the first evidence of BC200 expression in various tumour types [70]. This was followed by the work of Iacoangeli et al. who examined BC200 specifically in invasive and pre-invasive breast cancer [71].

Since there is existing information about BC200, its interacting proteins and proposed mechanisms of action from neuronal systems, it is possible that there are mechanistic overlaps in neoplastic cells. However, recent work by Singh et al. [28] provides the first evidence of BC200’s role in alternative splicing in breast cancer cells, something not observed previously in neurons. Therefore, BC200 might have roles in cancer initiation and/or progression that cannot be anticipated from previous studies.

2.2. History of BC200

2.2.1. Evolution of BC200

Unlike protein-coding RNAs, IncRNAs have limited sequence conservation among different species. This has caused significant debate because the lack of sequence conservation has led to the idea that IncRNAs are simply “transcriptional noise” [72]. Combined with challenges to test the functionality of many IncRNAs in homologous animal model systems [73], the biological functionality of the majority of IncRNAs remains to be discovered and robustly validated.

To better understand how IncRNAs became part of the human transcriptome, several mechanisms for the evolution of IncRNAs have been proposed [74]. Of those, one way that IncRNAs can emerge is by insertion of a transposable element into the genome that then becomes a functional transcriptional locus [74,75]. The first report of monkey BC200 highlights its sequence identity with a human Alu monomer [76] and refers to a retropositional event that led to BC200 [23].

By comparing the human BC200 (BCYRN1) gene sequence with the orthologous loci of the prosimians — galago, lemur and tarsier, Kuryshnev et al. established that BC200 is absent from prosimian lineages [77]. They proposed that the BC200 gene arose between 35 and 55 million years ago, due to the insertion of a monomeric Alu element in the lineage leading to primates (Anthropoidea) [77]. Through successive events of substitutions and insertions, the gene continued to evolve until the Homininae subfamily, composed of gorillas, chimpanzees and humans [77].

2.2.2. BC200 and 7SL RNA: a common Alu element

From its initial characterisation by Tiedge et al., in 1993, it was shown that human BC200 shared sequence similarity to 7SL RNA, the 300-nucleotide, non-coding RNA that forms the signal recognition particle (SRP) [25,78]. As mentioned earlier, BC200 has a 5’ Alu element that has very high sequence homology to the Alu-J repetitive element found in the human genome [78] and the Alu domain of 7SL RNA [25,76]. In terms of evolution, 7SL RNA is in fact the progenitor of BC200, and BC200 is the result of repositioning of Alu monomers, followed by exaptation into the human genome [79]. Importantly, the Alu region of both BC200 and 7SL genes contains A box and B box internal Pol III promoter elements for efficient transcription [25,80]. This region also contains the binding site for the SRP protein heterodimer, SRP9/14, as discussed below [81].

2.2.3. Analogues of BC200

Since the evolutionary event that led to the emergence of BC200 is relatively recent, no orthologs of BC200 have been identified outside of the primate order [37]. However, BC200 shares characteristics with IncRNAs in other species, suggesting that they could share similar functions in the cell [37,82].

Brain cytoplasmic 1 (BC1) is a non-coding RNA of 152 nucleotides that is specific to rodents [83,84]. In addition to sharing the same tissue and cellular localisation as BC200 in neuronal dendrites [25,84], BC1 is characterised by a tripartite structure, similar to BC200, comprised of a 5’ domain that forms an extended stem loop structure, a central A-rich region and a 3’ terminal stem loop structure [85]. This reflects its evolutionary origin by reposition of alanine transfer RNA (tRNAAla) [83]. Moreover, BC1 is transcribed by Pol III [39] and appears to play a role in translational regulation [86]. Indeed, BC1 and BC200, despite their independent evolutionary origins, have very similar sequences (Fig. 1B); therefore, it is not surprising that both of these non-coding RNAs interact with some of the same cellular proteins (Section 3).

Potential analogues to BC200 have also been found outside of mammals in Caenorhabditis elegans (C. elegans), although the C. elegans non-coding transcriptome is not fully characterised. A recent RNA sequencing study identified three potential analogues of BC200, based on the observation that the 5’ region of the non-coding RNAs inc394, inc465 and inc467 show high sequence similarity with the BC200 5’ Alu domain [87]. Similar to BC200 and BC1, each of the C. elegans transcripts contains an internal promoter element, approximately 10–20 nucleotides downstream of the transcription start site, suggesting that these RNAs could be transcribed by Pol III [87,88]. Further sequence analysis showed that inc394 shares the greatest similarity to BC200, with a sequence identity of up to 65% when sequence gaps are excluded [87]. In terms of functional analysis, inc394, inc465 and inc467, were shown to interact with the orthologous RNA binding complex, SRP9/14 [65,81,87]. While further characterisation of C. elegans non-coding RNAs is needed, it certainly raises the possibility that BC200 may have other analogues that will be uncovered with RNA sequencing approaches.

3. BC200 protein binding partners: a reflection of its function?

Since BC200, BC1 and 7SL RNAs share many sequence characteristics (Fig. 1C), it is plausible to assume that they could have overlapping functions in the cell through their interactions with proteins.

Here we highlight currently known BC200 protein binding partners and indicate that many proteins have been shown to also interact with BC1 or 7SL RNAs. By analysing these interactions and determining how these IncRNA-protein complexes affect cell function, future studies can apply this information to determine the role(s) that BC200 plays in cancer (Table 1).

3.1. BC200 and BC1 share protein partners

This section summarises information regarding a number of proteins that bind to both BC200 and BC1. Considering the neuronal expression of BC200 and BC1 [25,84], many of these studies focus specifically on interactions in the dendrites of neurons.

3.1.1. La protein

La protein is found in nearly all eukaryotic cells and is a human auto-antigen that binds to terminal poly-uridylate tails (UUU-3’OH) of Pol III transcripts [89,90]. It is involved in many different aspects of RNA metabolism and regulates the downstream processing of RNAs, including transport and cap-independent translation [91,92]. In their study, Kremerskotten et al. showed in vitro and in vivo that BC1 and BC200 interacts with La, and that the interaction with
BC200 was dependent on the 3' end of the transcript [63]. From this study, the authors propose that a La homodimer bridges the 5' Alu domain of BC200 to the ribosome to exert translational elongation arrest, together with SRP9/14 [63]. Another study, however, suggests that the interaction with BC200 and La is not part of a functional RNP complex in neuronal dendrites because the La protein cannot be detected [66].

### 3.1.2. Fragile X mental retardation protein (FMRP)

FMRP is a neuronal protein involved with messenger ribonucleoprotein (mRNP) transport and localised protein synthesis at synapses, which is critically important for synaptic plasticity [93–95]. Mutated or absent FMRP is responsible for the fragile X mental retardation syndrome, the most common cause of inherited mental retardation [94]. While FMRP is involved in mRNP transport and translational repression of mRNAs, it has also been shown to interact with BC200 and BC1 [68,96]. In their work, Zalfa and colleagues propose that the complex formed by FMRP and BC RNAs stabilizes or facilitates the interactions with FMRP-targeted mRNAs that are translationally repressed. In addition, they hypothesize that poly(A)-binding protein (PABP) might further stabilize this complex [96].

Interactions between BC200/BC1 and FMRP are not clear cut however. Kremerskothen et al. (1998) reported conflicting data, indicating that BC200 does not bind to FMRP [63]. While others report that FMRP and BC1 are unable to form a specific complex in vitro under physiological conditions [97]. Additionally in 2008, Iacoangeli et al. demonstrated that FMRP function in translational inhibition was independent of BC1 [98]. Moreover, they did not find evidence of an interaction between BC1 and FMRP in vitro or in vivo and show that FMRP is binding to mRNA targets in BC1 knockout mice, similar to that observed in wild-type animals [98]. Indeed, a subsequent study suggested that FMRP and BC1 RNA act in a sequential, but independent way to inhibit activity-stimulated translation [99]. Despite the efforts of many groups, the precise mechanisms of FMRP function through any engagement with BC200 lncRNA are still unclear.

### 3.1.3. Poly A-Binding protein (PABP)

PABP is an RNA-binding protein that binds mostly to the poly(A) tails of mRNA [100]. As both BC200 and BC1 non-coding RNAs have A-rich central domains (Fig. 1B), Muddasheety et al. investigated the possibility that PABP is associated with BC200/BC1 RNPs [66]. Since PABP influences translation initiation through an interaction with eu(karyotic) initiation factor 4G (eIF4G) [101], the authors proposed that BC200 and BC1 bind to PABP, forming stable RNP that can modulate translation initiation [66]. Alternatively, Kondrashov et al. (2005) suggested that BC200 exerts its translational inhibitory effects by acting as a competitor for PABP [102]. This is supported by a subsequent study that observed strong inhibitory effects of naked BC200/BC1 RNAs on translation in reticulocyte lysate and transfected cell systems, while the inclusion of PABP reduced this effect [61]. One conclusion from these studies is that other protein partners may also play a role in BC200-mediated translational repression. Such an example is eIF4A, which will be discussed below. Indeed, Lin et al. attribute less than 20% of translational repression competence to the sequestration of PABP by BC200 [62].

### 3.1.4. Purα

Purα is a single-stranded DNA and RNA-binding protein that is conserved throughout evolution and has multiple roles, from transcriptional activation to cell growth [103]. Using a knockout mouse system, it was demonstrated that Purα has an essential role in dendrite development [104]. As dendrites contain numerous localised mRNAs [105] and BC200/BC1 [25,84], Johnson et al. (2006) were the first to link Purα binding to an mRNA known to be translated in dendrites, microtubule-associated protein 1B mRNA (Map1B), and to BC200 and BC1 non-coding RNAs [104]. Interestingly, sequence complementarity between Map1B mRNA and BC200/BC1 RNAs had been noted in an earlier study [96]. Combining these observations, Johnson et al. proposed that Purα functions with BC200/BC1 to target certain mRNAs for localised translation in dendrites. This supports the hypothesis that BC200 may act as a linker between certain proteins and mRNAs, allowing transient regulation and/or modification. Indeed the possibility of BC200 interactions with other RNAs has not been fully explored, particularly outside of a neuronal context.

### 3.1.5. Eukaryotic initiation factor 4A (eIF4A) and eukaryotic initiation factor 4B (eIF4B)

Eukaryotic initiation factors are essential for translation initiation, including events such as cap-recognition and binding of the 48S pre-initiation complex to mRNAs [106]. To examine the role of
BC200/BC1 RNAs in this process, Wang and al. showed that BC1 is capable of inhibiting the formation of the 48 S initiation complex by targeting elf4A4, an ATP-dependent, RNA helicase [86]. In 2008, Lin et al. went on to show that BC200 and BC1 interfere with elf4A4's catalytic mechanism by blocking the factor's helicase activity, while enhancing its ATPase activity [62]. Both studies suggest a role in translational repression for these two non-coding RNAs.

Continuing with BC200’s effects on eukaryotic translation initiation factors, another report shows that neuronal BC RNAs mediate translational inhibition by binding to elf4B. In doing so, BC200/BC1 prevents this factor from interacting with 18 S ribosomal RNA (rRNA) in the small ribosomal subunit [59]. In this case, the BC RNAs are acting as competitors of 18 S rRNA for access to elf4B. In an extension of this work, a subsequent study demonstrated that BC RNA interactions with elf4B decrease upon neuronal stimulation that results in dephosphorylation of elf4B [60]. Once the BC RNAs have reduced affinity for dephosphorylated elf4B, the factor can fully participate in translation initiation [60]. Significantly, this work highlights the possibility of post-translational modifications as a level of regulation in BC200-protein complex formation and activity.

3.2. BC200 and 7SL – Alu-interacting heterodimer, signal recognition particle proteins 9 and 14 (SRP9/14)

Several studies have shown that SRP9/14 and BC200 interact [61,65,81]. SRP9/14 heterodimer is a well-known component of the signal recognition particle (SRP), an RNP that recognises and cotranslationally targets secretory proteins to the endoplasmic reticulum (ER) [107]. As mentioned earlier, 7SL RNA is a 300-nucleotide, non-coding RNA that forms the scaffold of SRP [78] and interacts with six polypeptides, SRP9/14, SRP19, SRP54, SRP68 and SRP72 [108]. In SRP, the heterodimer SRP9/14 mediates translation elongation arrest, pausing translation briefly to allow engagement between the signal sequence of the nascent polypeptide and the translocon machinery in the ER membrane [109,110].

Given the sequence conservation between BC200 and 7SL, Bovia et al. were the first to show that human SRP9/14 interacts with BC200 IncRNA; this result was subsequently confirmed in vivo by another group [65]. Unsurprisingly, rodent SRP9/14 does not interact with BC1, which does not have an Alu domain [81]; however, a recent study on BC200 analogues in C. elegans shows that inc394, inc465 and inc467 do interact with Cegaleans SRP9/14 [87]. It remains to be assessed whether this common characteristic between humans and Cegaleans has functional meaning.

Despite SRP9/14 and BC200’s involvement in translational events, the specific role of the interaction between the heterodimer and BC200, as components of an RNP complex, still remains unclear.

3.3. BC200-specific protein interactors

3.3.1. Synaptotagmin-binding, cytoplasmic, RNA-interacting protein (SYNCRIP)

SYNCRIP [64] is part of the heterogeneous nuclear ribonucleoprotein (hnRNP) family that is involved in splicing regulation, polyadenylation and other aspects of mRNA metabolism and transport [111]. The interaction between BC200 and SYNCRIP was first described in a study where the authors showed that the A-rich region of BC200 binds to SYNCRIP’s N-terminal RNA recognition motifs (RRMs) in vitro binding assays, combined with immunoprecipitation from human brain extracts [64]. SYNCRIP had previously been described as a component of RNA granules and was implicated in RNA localisation and/or translational control in dendrites [112–114]. Therefore, SYNCRIP could support BC200 translational repressor function by playing the role of a linker between neuronal RNA granules and the dendritic translation machinery [64].

As Duning et al. (2008) solely investigated BC200/SYNCRIP interaction in a neuronal context, it would be of interest to determine if a similar interaction exists in cancer cells. One possible lead regarding a potential link to cancer comes from Grosset et al. (2000), who discovered that the mRNA of the proto-oncogene, c-fos, is stabilised by a protein complex that includes NSAP1, also known as SYNCRIP [115]. Furthermore, this study discussed the role of SYNCRIP as a bridge between the major protein-coding region determinant of instability and the poly(A) tail of c-fos, thereby preventing its deadenylation and subsequent degradation [115]. Given the ability of BC200 to bind to both SYNCRIP and PABP, it is interesting to speculate whether the lncRNA might act as a scaffold to facilitate the interaction.

3.3.2. RNA helicase associated with AU-rich element (RHAU/ DHX36)

RHAU/DHX36 is an ATP-dependent, DEAD-box, RNA helicase that can unwind both DNA and RNA quadruplexes [116,117]. By performing RNA co-immunoprecipitation screens to identify novel RNAs that interact with RHAU, Booy and al. (2015) identified BC200 [118]. Contrary to the repressive control BC200 imposes on elf4A helicase activity, the BC200-RHAU interactions did not appear to impair RHAU helicase function; however, they did characterise a RHAU-dependent ability of BC200 to bind to unwound RNA quadruplex sequences [118]. From their work, the authors postulated that RHAU may recruit BC200 to stabilise and prevent refolding of unwound RNA quadruplexes [118], providing further evidence that BC200’s cellular roles will likely involve interactions with proteins and other RNAs.

3.3.3. Heterogeneous nuclear ribonucleoprotein E1 and E2 (hnRNP E1 and E2)

Besides SYNCRIP described above, other hnRNP family members also interact with BC200. Using yeast three-hybrid screening [119], Jang et al. (2016) identified two novel, candidate binding partners of BC200, hnRNP E1 and E2, that were subsequently confirmed by electromobility shift assays [120]. Given the role of BC200 in translational repression, the group investigated the link between these new interactors and this function. They found that translation of a luciferase reporter gene was inhibited by BC200; however, the addition of E1 and E2 relieved the inhibition [120]. Since this was an in vitro investigation, future work will likely examine whether the BC200 interacts with hnRNP E1 and E2 in vivo.

3.3.4. Heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNP A2/ B1)

Although nearly all of the previous studies suggest that BC200 function is related to translational repression, a recent study has reported that BC200 is involved in splicing through an interaction with the RNA-binding protein hnRNPA2/B1 in breast cancer cells [28]. Singh et al. (2016) sought to understand the mechanism of BC200, following the observation that BC200 is highly expressed in breast cancer cells [28]. To do this, they created a CRISPR/Cas9 generated, BC200 knockout cell line. Using the BC200 knockout cell line, they observed a suppression of cell growth, due to expression of Bcl-xS, the pro-apoptotic isofrom of Bcl-x [121]. Through subsequent experiments, the authors demonstrate that BC200 interacts with Bcl-x mRNA and hnRNPA2/A1. These interactions inhibit the splicing factor, Sam68, thereby promoting formation of the short, pro-apoptotic protein, Bcl-xS. In this scenario, BC200 plays an oncogenic role in breast cancer.
In conclusion, while some partners of BC200 are common with those of BC1 or 7SL RNAs, other studies have found specific protein interactors to BC200. While many of the identified BC200-binding proteins support a function for BC200 in translation repression, it is likely that BC200 RNPs are dynamic. With one study demonstrating that BC200 is involved in the regulation of the alternative splicing in cancer cells, this raises the question as to whether this function only appears in a disease context due to upregulation of BC200 expression. Based on the evidence so far, we suspect that BC200 is necessary at multiple regulatory levels, e.g. in transport of mRNA to the dendrite and followed by regulation of mRNA translation in the dendrite. It is quite possible that BC200 and its binding partners form RNA regulons to coordinate multiple cellular events.

4. BC200 RNA in disease contexts

Although lncRNAs are usually expressed at lower levels than protein-coding genes in physiological contexts, many lncRNAs have dysregulated expression in pathological contexts, such as neurodegenerative disorders or cancer. BC200 is not different in this regard (Table 2), and here we focus on our current understanding of BC200 expression in neurological disease and cancer and the utility of BC200 in a clinical context (Fig. 2).

| Pathology            | Tissue         | BC200 expression associated | Reference                             |
|----------------------|----------------|-----------------------------|---------------------------------------|
| Alzheimer’s Disease  | Brain          | Up/Down                     | [124–127]                             |
| Cancer               | Breast         | Up                          | [28,31,70,71,147–149]                 |
|                      | Cervix         | Up                          | [33]                                  |
|                      | Ovary          | Up/Down                     | [29,70]                               |
|                      | Lung           | Up                          | [27,70]                               |
|                      | Parotid        | Up                          | [70]                                  |
|                      | Tongue         | Up                          | [70]                                  |
|                      | Oesophagus     | Up                          | [70,150]                              |
|                      | Stomach        | Up                          | [32]                                  |
|                      | Colon          | Up                          | [34]                                  |

Fig. 2. Expression of BC200 in association with disease contexts.

BC200 lncRNA has been linked to many human diseases, mostly through observed alterations to its RNA expression levels in normal versus affected tissue or tumour (Table 2). To fully understand how BC200 can affect cells and influence diseases, detailed examination of its biological roles in each disease context is required. This will require biochemical characterisation of BC200’s molecular interactions and experimental determination of how these interactions directly influence cellular processes.
ages of 49 and 86 [125]. In comparison, BC200 RNA levels were significantly elevated in AD brain, compared to normal matched controls [125]. Since BC200 RNA was specifically observed in brain regions that are related to the disease, it was hypothesized that elevated BC200 RNA is involved with synaptodendritic deterioration in AD neurons [125]. However, this contradicts an earlier report that stated that AD-affected neocortex exhibits a 70% reduction in BC200 levels compared to age-matched controls [126]. While the difference might be explained by sampling location [123], BC200 appears to be dysregulated in AD [124]. Some studies have tried to understand the role of BC200 in AD, questioning whether it affects microtubule-dependent mRNA transport, contributing to axonal and dendritic blockage [124]. However, another study has linked BC200 with necrosis [127].

4.2. BC200 rodent analogue, BC1, is implicated in the regulation of neuronal receptors

At present, literature detailing the role of BC200 in neurological pathologies remains confined to AD. However, the rodent analogue BC1 has been documented to mediate signalling events within neurons. In a study lead by Centonze [128], BC1 knockout mice were used to assess the influence of this RNA on the dopamine D2 receptor (D2DR). D2DR is a G-protein coupled receptor found in dopaminergic neurons that upon stimulation initiates a range of signalling cascades that mediate various physiological responses [129]. Interestingly, the study by Centonze et al. [128] determined that BC1 is a regulator of dopamine transmission. The group concluded that the mechanism, though not fully defined, is not the result of direct translational regulation of the receptor. Instead, BC1 seemed to affect proteins involved in the receptor’s turnover and/or stability [128]. In another BC1 study, Zhong and co-workers [130] demonstrated that BC1 regulates group 1 metabotropic glutamate receptors (mGluRs) and is necessary for excitation-repression homeostasis in neurons. The absence of BC1 in vivo animal models was shown to provoke epileptogenic vulnerability, indicative of neuronal hyperexcitability [130]. Importantly both studies link BC1 regulatory RNA with neuronal receptor function and synaptic plasticity, which impacts overall brain function [93,131]. In humans, D2DR and mGluRs are implicated, and to some degree targeted therapeutically, in neurodegenerative diseases, including AD, Parkinson’s (PD) and Huntington’s (HD) [123].

Though BC200 shares extensive similarity with BC1 (Fig. 1C), the convergence of their functional roles, specifically in neuropathological contexts, remains to be fully explored. Despite the scientific investigations so far, the exact role of BC200 in AD and other neurodegenerative diseases is unclear, with further studies necessary.

4.2. BC200 in cancer

4.2.1. Association of BC200 with cancer

Since the discovery of the existence of lncRNAs, numerous studies have focused on identification, differential expression, and to a more limited degree, the underlying biological roles of lncRNAs in cancer. There are many excellent reviews on this topic [3,134,135]. Without doubt, the fast pace at which IncRNAs are being identified through RNA sequencing efforts is continuing [2,16,136]. While we have collated information about BC200’s association with cancer below, there are still many unanswered questions regarding how the IncRNA specifically influences the altered biology of a cancer cell. Given BC200’s many unique characteristics, i.e., Pol III transcript, mostly cytoplasmic localisation and small size, it may be that BC200 will occupy different functional roles, compared to more well-characterised, cancer-associated IncRNAs, such as MALAT1 and HOTAIR, that have nuclear roles in regulation of gene expression [137,138].

The initial suggestion that BC200 might have any role in cancer was described ten years ago. Fundamental work by Chen et al. [70] demonstrated that BC200 IncRNA was detectable in carcinomas of the breast, cervix, oesophagus, lung, ovary, parotid and tongue, while no expression was found in normal tissue, through immunohistochemistry analyses of tissue sections. The authors were the first to suggest a link between BC200 and the induction and/or progression of the tumour, but there was no molecular evidence to support that association directly [70].

While upregulation of BC200 RNA expression in cancer cells is not reflective of an overall increase in Pol III transcription [70], there is a report that BC200 expression is responsive to c-MYC and that c-MYC binds to the BC200 promoter region in non-small-cell lung cancer (NSCL) cells [27]. Given many cancers are driven by the MYC oncogene [42,43], it is quite possible that BC200 expression will be higher in MYC-driven cancers, although this has not been exhaustively examined. Interestingly a new report found that elevated Pol III transcription in early breast cancer tumourigenesis is driven by epigenetic changes, coupled with MYC [139]. Epigenetic control of BC200 expression is currently unknown.

4.2.2. Role of BC200 in cancer

Although the association between BC200 and cancer is established, numerous questions remain: how is BC200 expressed in cancer contexts, when it cannot be detected in normal tissue? Is the unusual BC200 pattern of expression functionally relevant with the cancer progression? Are there dynamic changes to a collective set of BC200-binding proteins? Does BC200 interact with other RNAs or DNA in cancer cells? What do the molecular interactions of BC200 tell us? Are certain pathways or cell behaviours particularly affected by modulation of BC200 lncRNA levels?

Recent studies are beginning to tackle the mechanisms of BC200 action and their impact in cancer cells. In 2015, Hu and al. showed that in NSCL cancer, the oncogenic transcription factor c-MYC binds to the BC200 promoter and induces its expression [27]. Moreover, they observe that in absence of BC200, migration and invasion is affected in vitro, corresponding with a reduction in the expression of the matrix metalloproteases, MMP9 and MMP13 [27]. Secretion of these enzymes by cancer cells is necessary for the initial steps of tumour cell invasion and metastasis [140]. Thus, the authors conclude that BC200 contributes to cell metastasis by promoting expression of MMP9 and MMP13 [27].

The observation that BC200 could contribute to metastasis is supported by another study that shows that after knockdown of BC200 in cervical carcinoma (HeLa) and breast cancer cell lines, cell migration is reduced [31]. However, instead of offering a mechanism involving MMPs, they propose that BC200 promotes migration and invasion by affecting the stability of the S100A11 mRNA, encoding a calcium sensing protein that is tightly associated with cell motility and invasiveness [31,141].

As described earlier, Singh et al. (2016) provided evidence of a novel regulatory function, with BC200 modulating alternative splicing of Bcl-x in the context of breast cancer [28]. Their work implies that BC200 plays an oncogenic role by negatively regulating apoptosis, allowing rogue cells to avoid cell death. In addition, their study indicated that the oestrogen receptor (ER) binds to the BC200 promoter, positively regulating its expression in breast cancer cell lines [28]. However, since most cases of advanced breast cancer have lost expression of ER [142,143], it seems likely that the expression of BC200 lncRNA may become dependent on other factors such as c-MYC as the tumour progresses [42,139,144].

In 2017 another study demonstrated that BC200 is critical for breast cancer cell survival [30]. They found that cell growth is inhibited, and apoptosis is induced, after knockdown of BC200 in
proliferating cells [30]. Leading on from this observation, this raises the possibility of BC200 as a candidate for specific drug targeting of tumour cells. The same study notes that the lethality of BC200 knockdown is restricted to actively proliferating cells [30], making BC200 an attractive cancer therapeutic target.

Adding to the existing literature, there have been a few studies published in 2018 indicating that BC200 is overexpressed in colon, stomach and cervical cancers [32–34]. In each of these studies, BC200 RNA levels were elevated in tumour versus adjacent normal tissues from patients, as determined by qRT-PCR. To begin to characterise how BC200 influences cancer cell behaviour, Ren et al. [32], Peng et al. [33] and Wu et al. [34] utilized corresponding cell lines to modulate BC200 expression by siRNA knockdown. Interestingly, each study revealed different possible mechanisms of BC200 action (Table 3). These included upregulation of EpCAM [32]; targeting of miRNA-138 [33]; and phosphorylation of signal transducer and activator of transcription 3 (STAT3) [34]. Further experiments will certainly focus on the similarities and differences of BC200’s cellular mechanisms among cancers with different tissue origins.

Collectively, BC200 been linked to three hallmarks of cancer [145] – cell proliferation, migration and resistance to apoptosis. Taken together, scientific findings thus far reinforce the idea that BC200 may be useful as potential therapeutic target in the treatment of multiple types of cancer.

4.2.3. Using BC200 as a cancer biomarker

As cancer research and treatment embraces new genome, transcriptome and proteome-wide technologies, there has been the emergence of “precision medicine” that heavily relies on the development and validation of biomarkers [146]. Here we highlight studies focused on the discovery of BC200 as a cancer biomarker.

In 2004, lacoangeli et al. were the first to propose the use of BC200 as a prognostic indicator of ductal carcinoma in situ (DCIS), a non-invasive form of breast cancer [71]. They argued that BC200 is a suitable marker, as the transcript is not detected in the early stages of DCIS but gradually increases as the tumour progresses to more advanced stages of DCIS and to invasive carcinoma [71,147]. Moreover, they showed that high expression of BC200 is associated with high, nuclear-grade DCIS, which is an indicator of aggressive cancer cell behaviour [71]. Collectively, the data supported the idea that BC200 might be involved in the regulation of cellular processes that affect breast cancer migration and invasiveness [148,149]. Indeed BC200’s involvement in breast cancer migration and invasiveness has been observed in subsequent studies [28,30].

Similar to studies in breast cancer, Zhao et al. showed that in oesophageal squamous cell carcinoma (ESCC), BC200 RNA expression is elevated in tumour cells compared to adjacent normal tissue [150]. Additionally they showed that high expression of BC200 RNA correlated with poor prognosis and shorter disease-free survival [150], suggesting that BC200 might be a useful prognostic marker for ESCC. Recent work by Hu et al. [27], Ren et al. [32], Peng et al. [33] and Wu et al. [34] presented similar findings of elevated BC200 RNA in tumour versus normal adjacent tissue from patient samples for lung, gastric, cervical and colon cancers. This suggests a role in tumour induction and/or progression, raising the possibility that BC200 could be clinically utilised for diagnostic and/or prognostic purposes.

Given the almost negligible expression in non-proliferating normal tissues, strong induction of BC200 may a reliable indicator of increased proliferation – one of the hallmarks of cancer [145]. Using BC200 as a biomarker may enable medical professionals and patients to make informed decisions regarding treatment, particularly given the correlation between transcript abundance and cancer progression. While this is the hope, practical use of BC200 as a cancer biomarker faces many challenges, based on the historically low success rate of clinical translation [146,151]. More realistically, it is possible that BC200 could be one of many lncRNAs to form an oncology non-coding RNA biomarker panel. This is an area that is currently undeveloped.

In summary, BC200 lncRNA has recently started to attract increased attention for its role in cancer. Although the specific details of its molecular mechanisms are currently unclear, BC200 appears to contribute to a number of different cancer hallmarks, including cell proliferation, migration and resistance to apoptosis [145]. Future work will likely reveal novel roles for BC200 lncRNA in cancer.

Table 3

Role of BC200 in cancer progression. BC200’s specific role in cancer progression remains an active area of investigation. However, some studies have begun to understand BC200’s mechanism of action. Although there will likely be additional context-dependent mechanisms identified, BC200 does affect several defining features of neoplastic cells, including increased cell proliferation, migration and resistance to apoptosis.

| Cancer tissue | Process affected | Mechanism | Reference |
|---------------|-----------------|-----------|-----------|
| Breast        | Proliferation   | Link with cell cycle progression | [28] |
|               | Apoptosis       | Regulation of Bcl-x alternative splicing | [39] |
|               | Cell migration  | Modulation of s100A11 mRNA stability | [29] |
| Cervix        | Proliferation and cell migration | Targeting microRNA-138 (miR138) | [33] |
| Lung          | Cell migration  | Regulation of MMP9 and MMP13 expression | [27] |
| Stomach       | Proliferation, apoptosis and cell migration | Regulation of EpCAM expression | [32] |
| Colon         | Proliferation and cell migration | STAT3 phosphorylation; regulation of β-catenin, cyclin D1, cyclin E and c-MYC expression | [34] |

5. Discussion

With an increasing number of studies focusing on the role of BC200, it is the shortest, long non-coding RNA that has an emerging importance in cancer biology. With this review, we aimed to summarise previous work on BC200, while highlighting outstanding questions regarding its role and molecular interactions, particularly in cancer.

Most of the RNA-protein interactions described here are specific to the neurological context where BC200 is naturally expressed. Studies in cancer have yet to replicate these results, and there is data suggesting that BC200 function in cancer might be different to its predicted role as a translational repressor [28]. Although most studies concur that BC200 is important in several key features of cancer – like cell proliferation, survival and migration, only few studies have been able to offer a mechanism that unravels its exact function. This will certainly be the focus of future research. Indeed, with tens of thousands of different long non-coding RNAs, only a handful have been functionally characterised in cancer, like MALAT and HOTAIR [152–155]. Therefore, a better understanding of BC200’s mechanism in cancer will contribute equally to research in cancer biology and to the general knowledge on long non-coding RNAs. Simultaneously, studies focusing on BC200 as a potential diagnostic biomarker of early-stage cancers must precisely identify
when its expression is detected, in addition to correlating BC200 expression with cancer development.

Acknowledgements

The authors would like to thank Mary Heapes for artwork and assistance with figures and Dr Paul Young for critical reading of the manuscript. SC is supported through the Government of Ireland Postgraduate Scholarship (GOIPG/2017/579), from the Irish Research Council. This work was supported by the Translational Research Access Programme, School of Medicine, University College Cork, Ireland.

References

[1] E. Birney, J.A. Stamatoyannopoulos, A. Dutta, R. Guigó, T.R. Gingeras, E.H. Margulies, et al., Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project, Nature 447 (2007) 799–816, https://doi.org/10.1038/nature05874.

[2] S. Djebali, C.A. Davis, A. Merkel, A. Dobin, T. Lassmann, A. Mortazavi, et al., Landscape of transcription in human cells, Nature 489 (2012) 101–108, https://doi.org/10.1038/nature11233.

[3] M. Huarte, The emerging role of IncRNAs in cancer, Nat. Med. 21 (2015) 1251–1261, https://doi.org/10.1016/j.nmed.2015.08.014.

[4] F.P. Marchese, I. Raimondi, M. Huarte, The multidimensional mechanisms of long non-coding RNA function, Genome Biol. 18 (2017) 206, https://doi.org/10.1186/s13059-017-1348-2.

[5] J.L. Rinn, H.Y. Chang, Genome regulation by long noncoding RNAs, Annu. Rev. Biochem. 81 (2012) 145–166, https://doi.org/10.1146/annurev-biochem-051410-110902.

[6] J.T.Y. Kung, D. Colognori, J.T. Lee, Long noncoding RNAs: past, present, and future, Genetics 193 (2013) 651–669, https://doi.org/10.1534/genetics.112.165704.

[7] I. Ulitsky, D.P. Bartel, IncRNAs: genomics, evolution, and mechanisms, Cell 154 (2013) 26–46, https://doi.org/10.1016/j.cell.2013.06.020.

[8] J.E. Wilusz, S.M. Freier, D.L. Spector, 3’ end processing of a long nuclear-retained noncoding RNA yields a 5‘RNA-like cytoplasmic RNA, Cell 135 (2008) 919–932, https://doi.org/10.1016/j.cell.2008.10.012.

[9] J.E. Wilusz, Long noncoding RNAs: Re-writing dogmas of RNA processing and regulation by long non-coding RNA, Dev. Reprod. Biol. 15 (2017) 177–186, https://doi.org/10.18632/nrb.204.

[10] J. Samson et al. / Non-coding RNA Research 3 (2018) 131–143
[150] R.H. Zhao, C.H. Zhu, X.K. Li, W. Cao, H. Zong, X.G. Cao, et al., BC200 LncRNA a potential predictive marker of poor prognosis in esophageal squamous cell carcinoma patients, OncoTargets Ther. 9 (2016) 2221–2226, https://doi.org/10.2147/OTT.S99401.

[151] G. Poste, Bring on the biomarkers, Nature 469 (2011) 156–157, https://doi.org/10.1038/469156a.

[152] T. Gutschner, M. Hammerle, S. Diederichs, MALAT1-A paradigm for long noncoding RNA function in cancer, J. Mol. Med. 91 (2013) 791–801, https://doi.org/10.1007/s00109-013-1028-y.

[153] M. Hajjari, A. Salavaty, HOTAIR : an oncogenic long non-coding RNA in different cancers, Canc. Biol. Med. 12 (2015) 1–9, https://doi.org/10.7407/jissan.2095-3941.2015.0006.

[154] W. Sun, Y. Yang, C. Xu, J. Guo, Regulatory mechanisms of long noncoding RNAs on gene expression in cancers, Canc. Genet. 216–217 (2017) 105–110, https://doi.org/10.1016/j.cancergen.2017.06.003.

[155] U.H. Weidle, F. Birzele, K. Gwen, R. Rüger, Long non-coding RNAs and their role in metastasis, Cancer genomics proteomics 14 (2017) 143–160, https://doi.org/10.21873/cgp.20027.

[156] M. Zuker, Mfold web server for nucleic acid folding and hybridization prediction, Nucleic Acids Res. 31 (2003) 3406–3415, https://doi.org/10.1093/nar/gkg595.

[157] P. Kerpedjiev, S. Hammer, I.L. Hofacker, Forna (force-directed RNA): simple and effective online RNA secondary structure diagrams, Bioinformatics 31 (2015) 3377–3379, https://doi.org/10.1093/bioinformatics/btv372.

[158] F. Corpet, Multiple sequence alignment with hierarchical clustering, Nucleic Acids Res. 16 (1988) 10881–10890.